The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

17 Jul 2020 12:02

RNS Number : 3768T
Evgen Pharma PLC
17 July 2020
 

 

 

 

 

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

 

 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Evgen Pharma plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

change in percentage of voting rights arising upon a new issue of shares by the issuer

 

3. Full name of person(s) subject to thenotification obligation: iii

Enterprise Ventures Limited

4. Full name of shareholder(s) (if different from 3.):iv

RisingStars Growth Fund II LP

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

15th July 2020

6. Date on which issuer notified:

17th July 2020

7. Threshold(s) that is/are crossed orreached: vi, vii

3%/2%/1%

      
 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights

Direct

Direct xi

Indirecti

Direct

Indirect

GB00BSVYN304

4,419,268

4,419,268

Nil

Nil

Nil

Nil

Nil

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

None

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

None

 

 

 

 

 

Nominal

Delta

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

Nil

Nil

                 
 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

 

Proxy Voting:

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will ceaseto hold:

 

12. Date on which proxy holder will cease to holdvoting rights:

 

 

13. Additional information:

 

14. Contact name:

Enterprise Ventures Limited

15. Contact telephone number:

 01772 270 570

   

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLKZGMNGNRGGZM
Date   Source Headline
17th Jun 20207:00 amRNSSFX-01 to be evaluated in COVID-19 trial
15th Jun 20205:05 pmRNSHolding(s) in Company
15th Jun 20207:00 amRNSFinal Results
8th Jun 20207:00 amRNSPaper on SFX-01 in ER positive breast cancer
5th Jun 20207:00 amRNSNotice of Results
15th May 202012:30 pmRNSStatement Re: Share Price Movement
30th Apr 20207:00 amRNSDirectorate Change
20th Feb 20209:27 amRNSHolding(s) in Company
13th Feb 20207:00 amRNSUniversity of Rochester Collaboration
6th Feb 20207:00 amRNSUniversity of Manchester collaboration discovery
29th Jan 20202:05 pmRNSSecond Price Monitoring Extn
29th Jan 20202:00 pmRNSPrice Monitoring Extension
20th Jan 20203:39 pmRNSHolding(s) in Company
17th Jan 20203:32 pmRNSHolding(s) in Company
8th Jan 20209:52 amRNSHolding(s) in Company
17th Dec 20197:01 amRNSInvestor presentation
17th Dec 20197:00 amRNSHalf-year Report
5th Dec 20197:00 amRNSMOU with The University of Dundee
4th Dec 20193:11 pmRNSNotice of Results
14th Nov 201911:59 amRNSHolding(s) in Company
11th Nov 201912:11 pmRNSSAS study clarification
11th Nov 20197:00 amRNSSFX-01 results in SAS study
30th Sep 20197:00 amRNSESMO presentation of Phase II STEM clinical data
23rd Sep 20197:00 amRNSUpdate on extended-use phase of STEM trial
5th Sep 20197:00 amRNSAgreement for supply of SFX-01 for autism trial
28th Aug 20197:00 amRNSUpdate on SAS study
7th Aug 20197:00 amRNSGrant of further European patent
5th Aug 20197:00 amRNSResearch collaboration
25th Jul 20191:00 pmRNSGrant of Options
18th Jul 20193:47 pmRNSResult of AGM
18th Jul 20197:00 amRNSAGM Statement
24th Jun 20197:00 amRNSSFX-01 featured in SAH review paper
19th Jun 201910:39 amRNSPosting of Annual Report and AGM Notice
13th Jun 20197:00 amRNSFull Year Results
11th Jun 20197:00 amRNSNotification of Preliminary Results
22nd May 20191:32 pmRNSHolding(s) in Company
21st May 20197:00 amRNSShare Option Exercise and Issue of Equity
9th May 20195:49 pmRNSHolding(s) in Company
9th May 201910:11 amRNSHolding(s) in Company
8th May 201911:29 amRNSResult of GM and Completion of Placing
26th Apr 201911:05 amRNSSecond Price Monitoring Extn
26th Apr 201911:00 amRNSPrice Monitoring Extension
24th Apr 201911:37 amRNSHolding(s) in Company
24th Apr 201911:33 amRNSHolding(s) in Company
23rd Apr 20192:05 pmRNSSecond Price Monitoring Extn
23rd Apr 20192:00 pmRNSPrice Monitoring Extension
23rd Apr 201910:30 amRNSHolding(s) in Company
18th Apr 20195:30 pmRNSPosting of Circular and Timing of General Meeting
17th Apr 20191:00 pmRNSPlacing and Notice of General Meeting
2nd Apr 20199:00 amRNSfinnCap publishes initiation research

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.